

Form PTO-1449
(Modified)

U.S. Department of Commerce
Patent and Trademark Office

Serial No.

Group Art Unit

Filing Date

Atty. Docket No.
Le A 33 861

FEB 26 2002

Applicant(s)

Lerchen, et al.

INFORMATION DISCLOSURE CITATION

FOREIGN PATENT DOCUMENTS

*	DOCUMENT NO.	DATE DD:MM:YY	COUNTRY	PRIMARY CLASS	SUB - CLASS	TRANSLATION	
						YES	NO
RT	F ₁ 9 3 2 0 2 2 9	14/10/93	WO				

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)

RT	R ₁	Uhm, J. H., Dooley, N. P., Kyritsis, A. P., Rao, J. S., Gladson, C. L., "Vitronectin, a Glioma-derived Extracellular Matrix Protein, Protects Tumor Cells from Apoptotic Death", Clinical Cancer Research, 5: 1587-1594 (June 1999)
	R ₂	Damiano, J. S., Cress, A. E., Hazlehurst, L. A., Shtil, A. A., Dalton, W. S., "Cell Adhesion Mediated Drug Resistance (CAM-DR): Role of Integrin and Resistance to Apoptosis in Human Myeloma Cell Lines", Blood, 93(5): 1658-1667 (March 1999)
	R ₃	Varner, J. A., Cheresh, D. A., "Integrins and Cancer", Current Opinion in Cell Biology, 8: 724-730 (1996)
	R ₄	Bitan, G., Scheibler, L., Greenberg, Z., Rosenblat, M., Chorev, M., "Mapping the Integrin $\alpha v \beta 3$ -Ligand Interface by Photoaffinity Cross-Linking", Biochemistry, 38: 3414-3420 (1999)
	R ₅	Fields, G. B., "Integrins: cell adhesion molecules in cancer", Exp. Opin. Ther. Patents, 8(6): 633-644 (1998)
	R ₆	Kerr, J. S., "Novel Small Molecule αv Integrin Antagonists: Comparative Anti-Cancer Efficacy with Known Angiogenesis Inhibitors", Anticancer Research, 19(2A): 959-968 (1999)
	R ₇	Carron, C. P., "A Peptidomimetic Antagonist of the Integrin $\alpha v \beta 3$ Inhibits Leydig Cell Tumor Growth and the Development of Hypercalcemia of Malignancy", Cancer Res., 58: 1930-1935 (May 1998)
	R ₈	Nickols, A., "Antiangiogenic and Anticancer Activities of Antagonists of Integrin $\alpha v \beta 3$ ", Proc. Annu. Meet. AACR., 38(1): 206 (March 1997), Abstract No. 1389
	R ₉	Macdonald, T. J., "Migration of Human Brain Tumor Cells and Human Brain Endothelial Cells on Tensin Requires the Integrin $\alpha v \beta 3$; a Unifying Model for Brain Tumor Invasion and Angiogenesis", Proc. Annu. Meet., AACR, 39: 497 (March 1998), Abstract No. 3382
	R ₁₀	Brooks, P. C., "Requirement of Vascular Integrin $\alpha v \beta 3$ for Angiogenesis", Science, 264: 569-571 (April 1994)
	R ₁₁	Brooks, P. C., "Integrin $\alpha v \beta 3$ Antagonists Promote Tumor Regression by Inducing Apoptosis of Angiogenic Blood Vessels", Cell, 79(7): 1157-1164 (Dec. 1994)
	R ₁₂	Varner, J. A., "Tumor Angiogenesis and The Role of Vascular Cell Integrin $\alpha v \beta 3$ ", Important Advances in Oncology, pp. 69-87 (1996)
	R ₁₃	Varner, J. A., "Review: The Integrin $\alpha v \beta 3$: Angiogenesis and Apoptosis", Cell Adhesion and Communication, 3(4): 367-374 (1995)

EXAMINER

R. Telle

DATE CONSIDERED

6/26/05

submitted on FEB 26 2002

BEST AVAILABLE COPY

Page 1 of 2

10/070208

26 FEB 2002

Form PTO-1449
(Modified)U.S. Department of Commerce
Patent and Trademark Office

Serial No.

Group Art. 1

Filing Date

Atty. Docket No.

FEB 26 2002

Le A 33 861

Applicant(s)

Lerchen, et al.

INFORMATION DISCLOSURE CITATION

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)

RT

R₁₄

Gasparini, G., "The Rationale and Future Potential of Angiogenesis Inhibitors in Neoplasma". Drugs. 58(1): 17-38 (July 1999)

R₁₅

Mueller, B. M., "Pre-clinical Therapy of Human Melanoma with Morpholino-doxorubicin Conjugated to a Monoclonal Antibody Directed Against an Integrin on Melanoma Cells", Antibody, Immunoconjugates, Radiopharm., 4(2): 99-106 (1991)

R₁₆

Sheu Joen, R., "Triflavin, an arg-gly-asp-containing peptide, inhibits the adhesion of tumor cells to matrix proteins via binding to multiple integrin receptors expressed on human hepatoma cells", Proc. Soc. Exp. Biol. Med., 213(1): 71-79 (1996)

EXAMINER

DATE CONSIDERED


R. Teller

6-26-05

Submitted on FEB 26 2002

BEST AVAILABLE COPY

Page 2 of 2



Form PTO-11 (2/01 revised)	U.S. Department of Commerce Patent and Trademark Office	Serial No. 10-070,208	Group Art Unit 1646	Filing Date 06/27/2002	Atty. Docket No. Le A 33 861
SUPPLEMENTAL INFORMATION DISCLOSURE CITATION			Applicant(s) Lerchen, et al.		
			RECEIVED		

NOV 20 2002

U.S. PATENT DOCUMENTS

TECH CENTER 1600/2900

*	DOCUMENT NO.	DATE MM/DD/YY	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
RT	U1 4 9 7 5 2 7 8	12/04/90	Senter, et al.	424	94.3	06/29/88
	U2 4 9 4 3 5 7 9	07/24/90	Vishnuvajjala, et al.	514	283	10/06/87
	U3 6 2 7 1 3 4 2	08/07/01	Lerchen, et al.	530	322	09/25/97
	U4 4 7 5 7 0 7 2	07/12/88	Kabbe, et al.	514	257	03/17/87
	U5 4 9 8 0 3 4 3	12/25/90	Stella, et al.	514	18	06/20/89
	U6 5 4 6 4 7 9 6	11/07/95	Petersen, et al.	514	312	06/11/92
	U7 5 9 5 5 1 0 0	09/21/99	Bosslet, et al.	424	450	05/24/95

FOREIGN PATENT DOCUMENTS

	DOCUMENT NO.	DATE DD/MM/YY	COUNTRY	PRIMARY CLASS	SUB- CLASS	TRANSLATION YES NO
RT	F2 9 4 0 5 6 8 1	17/03/94	WO			
	F3 0 5 1 1 9 1 7	04/11/92	EP			
	F4 8 8 0 7 3 7 8	06/10/88	WO			
	F5 9 6 0 2 5 4 6	01/02/96	WO			
	F6 9 8 1 0 7 9 5	19/03/98	WO			

EXAMINER


R. T. Allen

DATE CONSIDERED

6-26-05

To make and use considered, the date copy of this form with next communication is required.

BEST AVAILABLE COPY



F7	0	5	0	1	2	5	0	02/09/92	EP
F8	0	5	9	5	1	3	3	04/05/94	EP
F9	9	2	1	2	1	4	6	23/07/92	WO
F10	0	5	1	6	8	6	1	09/12/92	EP

RECEIVED

NOV 20 2002

TECH CENTER 1600/2900

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)

- R17 Ashwell, G., Harford, J., "Carbohydrate-Specific Receptors of the Liver", Ann. Rev. Biochem., 51: 531-554 (1982)
- R18 Aminoff, D., Bruegge, W., Bell, W., Sarpolis, K., Williams, R., "Role of Sialic Acid in Survival of Erythrocytes in the Circulation: Interaction of Neuraminidase-Treated and Untreated Erythrocytes With Spleen and Liver at the Cellular Level", Proc. Natl. Acad. Sci. USA, 74: 1521-1524 (April 1977)
- R19 Haltiwanger, R., Lehrman, M., Eckhardt, A., Hill, R., "The Distribution and Localization of the Fucose-Binding Lectin in Rat Tissues and the Identification of a High Affinity Form of the Mannose/N-Acetylglucosamine-Binding Lectin in Rat Liver", J. of Biol. Chem., 261: 7433-7439 (June 1986)
- R20 Jansen, R., Molema, G., Ching, T., Oosting, R., Harms, G., Moolenaar, F., Hardonk, M., Meijer, D., "Hepatic Endocytosis of Various Types of Mannose-Terminated Albumins", J. of Biol. Chem., 266: 3343-3348 (Feb., 1991)
- R21 Wall, M., Wani, M., Cook, C., Palmer, K., McPhail, A., Sim, G., "Plant Antitumor Agents. I. The Isolation and Structure of Camptothecin, A Novel Alkaloidal Leukemia and Tumor Inhibitor from Camptotheca Acuminata", J. of Am. Chem. Society, 88: 3888-3890 (August 1966)
- R22 Brooks, P., Montgomery, A., Rosenfeld, M., Reisfeld, R., Hu, T., Klier, G., Cheresch, D., "Integrin $\alpha\beta_3$ Antagonists Promote Tumor Regression by Inducing Apoptosis of Angiogenic Blood Vessels", Cell, 79: 1157-1164 (Dec., 1994)
- R23 Brooks, P., Stromblad, S., Klemke, R., Visscher, D., Sarkar, F., Cheresch, D., "Antiintegrin $\alpha\beta_3$ Blocks Human Breast Cancer Growth and Angiogenesis in Human Skin", J. Clin. Invest., 96: 1815-1822 (Oct., 1995)
- R24 Fitzpatrick, J., Garnett, M., "Design, Synthesis and In Vitro Testing of Methotrexate Carrier Conjugates Linked Via Oligopeptide Spacers", Anti-Cancer Drug Design, 10: 1-9 (1995)
- R25 Gabius, H., "Endogene Lektine in Tumoren Und Ihre Mogliche Bedeutung Fur Diagnose Und Therapie Von Krebserkrankungen", Onkologie, 12: 175-181 (April 1989)

R. Teller

DATE CONSIDERED

6-26-05

CONFIRMATION OF REVIEW OF INFORMATION RECEIVED FROM SOURCE FOR CONFORMANCE AND NOT CONSIDERED. Include copy of this form with next communication to applicant.

BEST AVAILABLE COPY